威斯康星州麦迪逊 - 以癌症筛查和诊断测试而闻名的Exact Sciences Corp. (NASDAQ: EXAS)公布了研究结果，显示多癌症早期检测 (MCED)测试取得进展。在圣地亚哥举行的美国癌症研究协会特别会议上展示的研究表明，一种新的多生物标志物方法可以提高癌症检测率，尤其是在早期阶段。

威斯康星州麦迪逊市—Exact Sciences Corp (NASDAQ:EXAS)总裁兼首席执行官Kevin Conroy近期大量购入公司普通股。根据最新的SEC文件显示，Conroy于11月13日以每股51.35美元的价格购入19,500股，总投资额为1,001,325美元。 此次交易使Conroy的直接持股增加到1,074,191股。此外，他还通过退休和信托账户间接持有公司股票，以及683 ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter, the fund ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, ...

Exact Sciences reported third-quarter results that fell short of analyst expectations and cut its guidance for the fourth ...

Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

Sustainability-assured statements ensure risks not captured by financial statements are properly disclosed and evaluated ...

Wells Fargo analyst Brandon Couillard assigned a Buy rating to Exact Sciences (EXAS – Research Report) yesterday and set a price target ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday. Puneet Souda’s ...